Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
United Therapeutics Corporation
About
  2. Companies
  3. United Therapeutics Corporation
  4. Products
  5. Bioengineered Organs for ...

Bioengineered Organs for Transplantation

SHARE

Miromatrix is developing bioengineered organs for transplantation, and our technology can be applied across the spectrum of donor needs. We are currently focused on bioengineering transplantable kidneys (MiroKidney) and livers (MiroLiver), but we believe our technology can be used to engineer other in-demand organs, such as lungs, pancreases, hearts and other internal organs or vascularized tissues. 

Most popular related searches
end-stage liver disease
end-stage kidney disease
liver transplant
kidney transplant
chronic kidney disease
organ transplant
disease control
liver disease
vascularized tissue
vascular tissue

End-stage renal disease (ESRD), which is the final stage of chronic kidney disease and 9th leading cause of death in the United States, affects an estimated 100,000 people each year in the U.S. These patients join the over 550,000 patients in America that either require chronic dialysis or dialysis while waiting for a kidney transplant. In 2018, there were more than 100,000 patients on the kidney transplant waitlist in the U.S. but only ~21,000 received a transplant. The only curative therapy for ESRD is a kidney transplant, yet the shortage of donor kidneys means many patients languish on the transplant waitlist for years while undergoing expensive and time-consuming dialysis treatment. A commercially available bioengineered kidney could save the healthcare system billions of dollars annually and provide a permanent treatment for patients with ESRD to greatly increase their quality of life.

Miromatrix is bioengineering transplantable kidneys based on our patented perfusion decellularization and recellularization technology in an effort to provide new options to the thousands of patients who need a kidney transplant and to replace dialysis. Our efforts and progress have been recently recognized as a KidneyX Phase I prize winner targeted at redesigning dialysis and align with the recent Executive Order prioritizing an artificial kidney. The need for new renal therapies is enormous and we are focused on bringing forward this life-saving technology.

End-stage liver disease (ESLD) is the 12th leading cause of death in the United States, accounting for ~44,000 deaths annually, according to the Centers for Disease Control (CDC). The only curative therapy for ESLD is liver transplantation, and livers are one of the most sought after donor organs in the world. Unfortunately, the success of liver transplantation has led to its greatest challenge: the shortage of available organs. Nationally, about 16,000 patients each year are waiting for a liver transplant, yet just half will receive one in time. We want to change that.

Miromatrix is bioengineering transplantable livers based on our patented perfusion decellularization and recellularization technology in an effort to provide new options to the thousands of patients in need of a liver transplant.  In our state-of-the-art facilities, we are scaling to clinical sized implants and recently achieved a major milestone: successfully revascularizing a decellularized porcine liver graft with human vascular cells and sustaining perfusion for 15 days post-transplantation. We are focused on bringing forward this life-saving technology and providing a permanent treatment solution for patients with ESLD.